HR. 1672In Committee
Maintaining Investments in New Innovation Act
Requires genetically targeted drug products to have at least 11 years of market approval before they can be selected for Medicare drug price negotiation
Plain-English overview
What this bill does
Requires genetically targeted drug products to have at least 11 years of market approval before they can be selected for Medicare drug price negotiation
Key points
- Require 11 years market approval
- Modify Medicare drug negotiation eligibility
Current status
Where it stands
Status
In Committee
Latest action
2025-02-27 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related context
Topics and policy areas
undefinedGeneticsHealthMedicarePrescription drugs